九安医疗(002432) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 reached ¥21,736,870,739.50, a significant increase of 6,646.79% compared to the same period last year[3] - Net profit attributable to shareholders was ¥14,311,867,476.47, reflecting a growth of 37,527.35% year-over-year[3] - The net profit after deducting non-recurring gains and losses was ¥14,345,134,092.22, marking a staggering increase of 756,669.14% compared to the previous year[3] - The net cash flow from operating activities was ¥12,719,185,146.12, a turnaround from a negative cash flow of ¥37,538,104.40 in the same quarter last year, representing a growth of 33,983.40%[3] - Basic earnings per share (EPS) increased to ¥31.3920, up 36,875.27% from ¥0.0849 in the previous year[3] - Total operating revenue for the current period reached ¥21,736,870,739.50, a significant increase from ¥322,180,761.49 in the previous period, reflecting a growth of approximately 6,635%[15] - Total operating costs amounted to ¥4,844,206,985.44, compared to ¥327,152,582.63 in the prior period, indicating a rise of about 1,480%[15] - Net profit for the current period was ¥15,257,942,841.81, down from ¥22,073,582.57 in the previous period, representing a decrease of approximately 30.5%[16] - The total comprehensive income for the current period was ¥15,245,031,404.27, down from ¥25,437,912.70 in the previous period, indicating a decline of approximately 40%[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥20,451,740,484.17, a 420.36% increase from the end of the previous year[3] - Shareholders' equity attributable to the parent company reached ¥17,214,314,873.10, up 499.26% from the previous year[3] - Total liabilities have increased to approximately ¥2.33 billion from ¥1.09 billion[13] - Accounts receivable increased significantly to ¥4.27 billion from ¥589.46 million[12] - Inventory has risen to ¥1.19 billion from ¥627.82 million[12] - Total assets have increased to approximately ¥20.45 billion from ¥3.93 billion[14] Cash Flow - The company's current cash and cash equivalents amount to approximately ¥13.27 billion, up from ¥895.59 million at the beginning of the year[11] - Cash inflow from operating activities totaled ¥17,833,437,850.37, significantly higher than ¥313,896,701.96 in the prior period, marking an increase of over 5,570%[18] - The net cash flow from operating activities was CNY 12,719,185,146.12, a significant increase compared to a negative cash flow of CNY -37,538,104.40 in the previous period[20] - The total cash outflow from investing activities was CNY 333,433,575.86, resulting in a net cash flow from investing activities of CNY -114,035,009.53, compared to CNY -87,268,238.57 previously[20] - The cash inflow from financing activities was CNY 880,892.00, while the cash outflow totaled CNY 204,271,662.27, leading to a net cash flow from financing activities of CNY -203,390,770.27[20] - The ending balance of cash and cash equivalents was CNY 12,938,770,737.53, up from CNY 540,826,515.65 at the beginning of the period[21] - The company reported a total cash outflow from operating activities of CNY 5,114,252,704.25, compared to CNY 351,434,806.36 in the previous period[20] Shareholder Information - The company reported a total of 176,866 common shareholders at the end of the reporting period[6] - The largest shareholder, Shihezi Sanhe Equity Investment Partnership, held 22.74% of the shares, amounting to 109,497,902 shares[6] Contracts and Orders - The total order amount for iHealth test kits from the New York State Department of Health is $65,310,000, including shipping[10] - The sales contract with the New York State Department of Health for iHealth test kits totals $120,000,000, including shipping[10] - The contract with the Massachusetts Department of Public Health for iHealth test kits amounts to $148,327,400, including shipping[10] - A new procurement contract for 250 million iHealth test kits was signed with the U.S. HHS, totaling $1,275,000,000, including shipping[10] - The amended contract increased the total amount to $1,774,999,992, adding 104,166,665 additional test kits[10] Expenses and Losses - The company experienced a credit impairment loss of ¥187,112,406.72, compared to a loss of ¥3,696,874.37 in the previous period, indicating a notable increase in credit risk[16] - Other comprehensive income after tax was reported at -¥12,911,437.54, contrasting with a gain of ¥3,364,330.13 in the previous period[16] - The company recorded an investment loss of ¥1,919,799.05, compared to a gain of ¥206,435.60 in the prior period, reflecting a downturn in investment performance[15] - The company’s research and development expenses increased to ¥60,553,065.68 from ¥39,955,815.11, representing a growth of about 51.5%[15] Audit Information - The company did not conduct an audit for the first quarter report[22]